Drug Profile

RNA vaccine - aVaxziPen/Imperial College of Science

Alternative Names: Thermostable RNA vaccine - aVaxziPen/Imperial College London

Latest Information Update: 28 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enesi Pharma; Imperial College of Science, Technology and Medicine
Developer aVaxziPen; Imperial College of Science, Technology and Medicine
Class COVID-19 vaccines; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Jan 2025 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in United Kingdom (Transdermal)
18 Dec 2020 Enesi Pharma and Imperial College London enters into collaboration agreement to develop thermostable RNA vaccines
18 Dec 2020 Early research in COVID-2019 infections (Prevention) in United Kingdom (Transdermal)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com